BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maasoumy B, Wiegand SB, Jaroszewicz J, Bremer B, Lehmann P, Deterding K, Taranta A, Manns MP, Wedemeyer H, Glebe D, Cornberg M. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect 2015;21:606.e1-10. [PMID: 25700889 DOI: 10.1016/j.cmi.2015.02.010] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Hsu YC, Suri V, Nguyen MH, Huang YT, Chen CY, Chang IW, Tseng CH, Wu CY, Lin JT, Pan DZ, Gaggar A, Podlaha O. Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation. Gastroenterology 2022;162:1160-1170.e1. [PMID: 34995536 DOI: 10.1053/j.gastro.2021.12.286] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
2 Carey I, Gersch J, Wang B, Moigboi C, Kuhns M, Cloherty G, Dusheiko G, Agarwal K. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy. Hepatology 2020;72:42-57. [PMID: 31701544 DOI: 10.1002/hep.31026] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 26.5] [Reference Citation Analysis]
3 Höner zu Siederdissen C, Maasoumy B, Cornberg M. What is new on HBsAg and other diagnostic markers in HBV infection? Best Practice & Research Clinical Gastroenterology 2017;31:281-9. [DOI: 10.1016/j.bpg.2017.04.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
4 Chen EQ, Feng S, Wang ML, Liang LB, Zhou LY, Du LY, Yan LB, Tao CM, Tang H. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B. Sci Rep. 2017;7:173. [PMID: 28282964 DOI: 10.1038/s41598-017-00111-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
5 Shimakawa Y, Ndow G, Njie R, Njai HF, Takahashi K, Akbar SMF, Cohen D, Nayagam S, Jeng A, Ceesay A, Sanneh B, Baldeh I, Imaizumi M, Moriyama K, Aoyagi K, D'Alessandro U, Mishiro S, Chemin I, Mendy M, Thursz MR, Lemoine M. Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa. Clin Infect Dis 2020;70:1442-52. [PMID: 31102406 DOI: 10.1093/cid/ciz412] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
6 Zhang ZQ, Shi BS, Lu W, Liu DP, Huang D, Feng YL. Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection. Can J Infect Dis Med Microbiol 2019;2019:6545642. [PMID: 31949546 DOI: 10.1155/2019/6545642] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Aliabadi E, Urbanek-Quaing M, Maasoumy B, Bremer B, Grasshoff M, Li Y, Niehaus CE, Wedemeyer H, Kraft ARM, Cornberg M. Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. Gut 2021:gutjnl-2021-324646. [PMID: 34702717 DOI: 10.1136/gutjnl-2021-324646] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
8 Lin CL, Kao JH. New perspectives of biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol. 2016;22:423-431. [PMID: 28081591 DOI: 10.3350/cmh.2016.0069] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
9 Sandmann L, Yurdaydin C, Deterding K, Heidrich B, Hardtke S, Lehmann P, Bremer B, Manns MP, Cornberg M, Wedemeyer H, Maasoumy B; HIDIT-II Study Group. HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. Hepatol Commun 2021. [PMID: 34561972 DOI: 10.1002/hep4.1821] [Reference Citation Analysis]
10 Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2018;47:43-54. [PMID: 29035003 DOI: 10.1111/apt.14376] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 16.0] [Reference Citation Analysis]
11 Zhang ZQ, Zhang XN, Lu W, Wang YB, Weng QC, Feng YL. Distinct patterns of serum hepatitis B core-related antigen during the natural history of chronic hepatitis B. BMC Gastroenterol 2017;17:140. [PMID: 29202690 DOI: 10.1186/s12876-017-0703-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
12 Ghany MG, King WC, Lisker-Melman M, Lok ASF, Terrault N, Janssen HLA, Khalili M, Chung RT, Lee WM, Lau DTY, Cloherty GA, Sterling RK. Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. Hepatology 2021;74:2395-409. [PMID: 34133774 DOI: 10.1002/hep.32018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
13 Chung RT, King WC, Ghany MG, Lisker-Melman M, Hinerman AS, Khalili M, Sulkowski M, Jain MK, Choi EK, Nalesnik MA, Bhan AK, Cloherty G, Wong DK, Sterling RK; HBV-HIV Cohort Study of the Hepatitis B Research Network. A prospective cohort study of novel markers of hepatitis B virus replication in human immunodeficiency virus coinfection. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01362-8. [PMID: 34973459 DOI: 10.1016/j.cgh.2021.12.038] [Reference Citation Analysis]
14 Suzuki Y, Maekawa S, Komatsu N, Sato M, Tatsumi A, Miura M, Matsuda S, Muraoka M, Nakakuki N, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Inoue T, Sato T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. HBV preS deletion mapping using deep sequencing demonstrates a unique association with viral markers. PLoS One 2019;14:e0212559. [PMID: 30794632 DOI: 10.1371/journal.pone.0212559] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Rybicka M, Bielawski KP. Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection. Microorganisms. 2020;8. [PMID: 32942584 DOI: 10.3390/microorganisms8091416] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
16 Watanabe T, Hayashi S, Tanaka Y. Drug Discovery Study Aimed at a Functional Cure for HBV. Viruses 2022;14:1393. [DOI: 10.3390/v14071393] [Reference Citation Analysis]
17 Watanabe T, Inoue T, Tanaka Y. Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B. Microorganisms 2021;9:2083. [PMID: 34683404 DOI: 10.3390/microorganisms9102083] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Chuaypen N, Posuwan N, Chittmittraprap S, Hirankarn N, Treeprasertsuk S, Tanaka Y, Shinkai N, Poovorawan Y, Tangkijvanich P. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy. Clin Microbiol Infect 2018;24:306.e7-306.e13. [PMID: 28750917 DOI: 10.1016/j.cmi.2017.07.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
19 Wübbolding M, Lopez Alfonso JC, Lin CY, Binder S, Falk C, Debarry J, Gineste P, Kraft ARM, Chien RN, Maasoumy B, Wedemeyer H, Jeng WJ, Meyer Hermann M, Cornberg M, Höner Zu Siederdissen C. Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB. Hepatol Commun 2021;5:97-111. [PMID: 33437904 DOI: 10.1002/hep4.1626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Yang HC, Shih YF, Liu CJ. Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B. J Infect Dis 2017;216:S757-64. [PMID: 29156050 DOI: 10.1093/infdis/jix461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
21 Vachon A, Osiowy C. Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management. Viruses 2021;13:951. [PMID: 34064049 DOI: 10.3390/v13060951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Mak LY, Seto WK, Fung J, Yuen MF. Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. Hepatol Int 2020;14:35-46. [PMID: 31745711 DOI: 10.1007/s12072-019-09998-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
23 Ghany MG, King WC, Lisker-Melman M, Lok ASF, Terrault N, Janssen HLA, Khalili M, Chung RT, Lee WM, Lau DTY, Cloherty GA, Sterling RK. Reply. Hepatology 2022;75:761-3. [PMID: 34800047 DOI: 10.1002/hep.32251] [Reference Citation Analysis]
24 Wong DK, Seto W, Cheung K, Chong C, Huang F, Fung J, Lai C, Yuen M. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int 2017;37:995-1001. [DOI: 10.1111/liv.13346] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 13.6] [Reference Citation Analysis]
25 Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol 2020;26:261-79. [PMID: 32536045 DOI: 10.3350/cmh.2020.0032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
26 Huang D, Wu D, Wang P, Wang Y, Yuan W, Hu D, Hu J, Wang Y, Tao R, Xiao F, Zhang X, Wang X, Han M, Luo X, Yan W, Ning Q. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol 2022:S0168-8278(22)00066-6. [PMID: 35149125 DOI: 10.1016/j.jhep.2022.01.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Pumpens P, Grens E. The true story and advantages of the famous Hepatitis B virus core particles: Outlook 2016. Mol Biol 2016;50:489-509. [DOI: 10.1134/s0026893316040099] [Cited by in Crossref: 10] [Article Influence: 1.7] [Reference Citation Analysis]
28 Lee HW, Ahn SH, Chan HL. Hepatitis B Core-Related Antigen: From Virology to Clinical Application. Semin Liver Dis 2021;41:182-90. [PMID: 33957693 DOI: 10.1055/s-0041-1723088] [Reference Citation Analysis]
29 van Campenhout MJ, Brouwer WP, van Oord GW, Xie Q, Zhang Q, Zhang N, Guo S, Tabak F, Streinu-Cercel A, Wang J, Pas SD, Sonneveld MJ, de Knegt RJ, Boonstra A, Hansen BE, Janssen HL. Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Microbiol Infect 2016;22:571.e5-9. [PMID: 26898481 DOI: 10.1016/j.cmi.2016.02.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
30 Loggi E, Gitto S, Gabrielli F, Franchi E, Seferi H, Cursaro C, Andreone P. Virological Treatment Monitoring for Chronic Hepatitis B. Viruses 2022;14:1376. [DOI: 10.3390/v14071376] [Reference Citation Analysis]
31 Tseng C, Liu W, Chen C, Chang T, Tseng K. Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07326-1] [Reference Citation Analysis]
32 Zoulim F, Fournier C, Habersetzer F, Sprinzl M, Pol S, Coffin CS, Leroy V, Ma M, Wedemeyer H, Lohse AW, Thimme R, Lugardon K, Martin P, Bastien B, Sansas B, Adda N, Halluard C, Bendjama K, Brandely M, Inchauspé G. Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. Hum Vaccin Immunother 2020;16:388-99. [PMID: 31373537 DOI: 10.1080/21645515.2019.1651141] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
33 Wang L, Cao X, Wang Z, Gao Y, Deng J, Liu X, Zhuang H. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients. J Clin Microbiol 2019;57:e01303-18. [PMID: 30355757 DOI: 10.1128/JCM.01303-18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
34 Hadziyannis E, Laras A. Viral Biomarkers in Chronic HBeAg Negative HBV Infection. Genes (Basel) 2018;9:E469. [PMID: 30262738 DOI: 10.3390/genes9100469] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
35 Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology 2019. [PMID: 31713892 DOI: 10.1002/hep.31030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
36 Höner Zu Siederdissen C, Maasoumy B, Cornberg M. New viral biomarkers for Hepatitis B: Are we able to change practice? J Viral Hepat 2018;25:1226-35. [PMID: 30187603 DOI: 10.1111/jvh.12993] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
37 Loggi E, Vukotic R, Conti F, Grandini E, Gitto S, Cursaro C, Galli S, Furlini G, Re MC, Andreone P. Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2019;26:568-75. [PMID: 30576048 DOI: 10.1111/jvh.13054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
38 Cornberg M, Lok AS, Terrault NA, Zoulim F, Berg T, Brunetto MR, Buchholz S, Buti M, Chan HL, Chang K, Dandri M, Dusheiko G, Feld JJ, Ferrari C, Ghany M, Janssen HL, Kennedy P, Lampertico P, Liang J, Locarnini S, Maini MK, Mishra P, Papatheodoridis G, Petersen J, Schlottmann S, Wang S, Wedemeyer H. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. Journal of Hepatology 2020;72:539-57. [DOI: 10.1016/j.jhep.2019.11.003] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 30.0] [Reference Citation Analysis]
39 Dezanet LNC, Maylin S, Gabassi A, Rougier H, Miailhes P, Lascoux-Combe C, Chas J, Girard PM, Delaugerre C, Zoulim F, Lacombe K, Boyd A. Correlation of serum hepatitis B core-related antigen with hepatitis B virus total intrahepatic DNA and covalently closed circular-DNA viral load in HIV-hepatitis B coinfection. AIDS 2020;34:1943-9. [PMID: 32773480 DOI: 10.1097/QAD.0000000000002659] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Chi XM, Wang XM, Wang ZF, Wu RH, Gao XZ, Xu HQ, Ding YH, Niu JQ. Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B. World J Gastroenterol 2021; 27(40): 6927-6938 [PMID: 34790015 DOI: 10.3748/wjg.v27.i40.6927] [Reference Citation Analysis]
41 Dolman GE, Koffas A, Mason WS, Kennedy PT. Why, who and when to start treatment for chronic hepatitis B infection. Curr Opin Virol. 2018;30:39-47. [PMID: 29655092 DOI: 10.1016/j.coviro.2018.03.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
42 Riveiro-Barciela M, Bes M, Rodríguez-Frías F, Tabernero D, Ruiz A, Casillas R, Vidal-González J, Homs M, Nieto L, Sauleda S, Esteban R, Buti M. Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus genotype. Clin Microbiol Infect 2017;23:860-7. [PMID: 28288829 DOI: 10.1016/j.cmi.2017.03.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
43 Alidjinou EK, Michel C, Canva V, Ajana F, Hober D, Bocket L. Very slow decline of hepatitis B virus surface antigen and core related antigen in chronic hepatitis B patients successfully treated with nucleos(t)ide analogues. J Med Virol 2018;90:989-93. [PMID: 29315722 DOI: 10.1002/jmv.25028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Chan HLY, Yasuda S, Wong GLH, Tada T, Chan CKM, Kumada T, Tse YK, Wong VWS, Toyoda H. Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B. J Gastroenterol Hepatol 2020;35:2202-9. [PMID: 32293740 DOI: 10.1111/jgh.15058] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Baudi I, Inoue T, Tanaka Y. Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. Int J Mol Sci. 2020;21. [PMID: 32023902 DOI: 10.3390/ijms21030949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
46 Rajoriya N, Combet C, Zoulim F, Janssen HLA. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? J Hepatol. 2017;67:1281-1297. [PMID: 28736138 DOI: 10.1016/j.jhep.2017.07.011] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 13.4] [Reference Citation Analysis]
47 Squires JE, Balistreri WF. Hepatitis C virus infection in children and adolescents. Hepatol Commun. 2017;1:87-98. [PMID: 29404447 DOI: 10.1002/hep4.1028] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 8.6] [Reference Citation Analysis]
48 Yang HC, Kao JH. Looking into the crystal ball: biomarkers for outcomes of HBV infection. Hepatol Int 2016;10:99-101. [PMID: 26732689 DOI: 10.1007/s12072-015-9698-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
49 Yoshida K, Desbiolles A, Feldman SF, Ahn SH, Alidjinou EK, Atsukawa M, Bocket L, Brunetto MR, Buti M, Carey I, Caviglia GP, Chen EQ, Cornberg M, Enomoto M, Honda M, Zu Siederdissen CH, Ishigami M, Janssen HLA, Maasoumy B, Matsui T, Matsumoto A, Nishiguchi S, Riveiro-Barciela M, Takaki A, Tangkijvanich P, Toyoda H, van Campenhout MJH, Wang B, Wei L, Yang HI, Yano Y, Yatsuhashi H, Yuen MF, Tanaka E, Lemoine M, Tanaka Y, Shimakawa Y. Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. Clin Gastroenterol Hepatol 2021;19:46-60.e8. [PMID: 32360825 DOI: 10.1016/j.cgh.2020.04.045] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
50 Caviglia GP, Abate ML, Noviello D, Olivero A, Rosso C, Troshina G, Ciancio A, Rizzetto M, Saracco GM, Smedile A. Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α: HBcrAg kinetics in CHB therapy. Hepatol Res 2017;47:747-54. [DOI: 10.1111/hepr.12811] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
51 Wu T, Kwok RM, Tran TT. Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues. Am J Gastroenterol 2017;112:1780-8. [PMID: 29087395 DOI: 10.1038/ajg.2017.397] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
52 Lok J, Dusheiko G, Carey I, Agarwal K. Review article: Novel biomarkers in hepatitis B infection. Aliment Pharmacol Ther 2022. [PMID: 35770458 DOI: 10.1111/apt.17105] [Reference Citation Analysis]
53 Dusheiko G. Current and future directions of management of hepatitis B: steps toward a cure. Future Virology 2018;13:189-209. [DOI: 10.2217/fvl-2017-0103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Honda M, Shirasaki T, Terashima T, Kawaguchi K, Nakamura M, Oishi N, Wang X, Shimakami T, Okada H, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Kaneko S. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma. J Infect Dis. 2016;213:1096-1106. [PMID: 26621908 DOI: 10.1093/infdis/jiv572] [Cited by in Crossref: 52] [Cited by in F6Publishing: 59] [Article Influence: 7.4] [Reference Citation Analysis]
55 Lindh M, Rydell GE, Larsson SB. Impact of integrated viral DNA on the goal to clear hepatitis B surface antigen with different therapeutic strategies. Curr Opin Virol 2018;30:24-31. [PMID: 29453099 DOI: 10.1016/j.coviro.2018.01.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
56 Martinot-peignoux M, Lapalus M, Maylin S, Boyer N, Castelnau C, Giuily N, Pouteau M, Moucari R, Asselah T, Marcellin P. Baseline HBsAg and HBcrAg titres allow peginterferon-based ‘precision medicine’ in HBeAg-negative chronic hepatitis B patients. J Viral Hepat 2016;23:905-11. [DOI: 10.1111/jvh.12565] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
57 Flisiak R, Jaroszewicz J, Łucejko M. siRNA drug development against hepatitis B virus infection. Expert Opin Biol Ther 2018;18:609-17. [PMID: 29718723 DOI: 10.1080/14712598.2018.1472231] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
58 Mak LY, Seto WK, Fung J, Yuen MF. New Biomarkers of Chronic Hepatitis B. Gut Liver. 2019;13:589-595. [PMID: 30919601 DOI: 10.5009/gnl18425] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
59 Chuaypen N, Posuwan N, Payungporn S, Tanaka Y, Shinkai N, Poovorawan Y, Tangkijvanich P. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Int 2016;36:827-36. [DOI: 10.1111/liv.13046] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
60 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398. [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021] [Cited by in Crossref: 1805] [Cited by in F6Publishing: 1711] [Article Influence: 361.0] [Reference Citation Analysis]
61 Liu J, Goicochea P, Block T, Brosgart CL, Donaldson EF, Lenz O, Gee Lim S, Marins EG, Mishra P, Peters MG, Miller V. Advancing the regulatory path on hepatitis B virus treatment and curative research: a stakeholders consultation. Journal of Virus Eradication 2017;3:1-6. [DOI: 10.1016/s2055-6640(20)30302-2] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
62 Kuhns MC, Holzmayer V, Anderson M, McNamara AL, Sauleda S, Mbanya D, Duong PT, Dung NTT, Cloherty GA. Molecular and Serological Characterization of Hepatitis B Virus (HBV)-Positive Samples with Very Low or Undetectable Levels of HBV Surface Antigen. Viruses 2021;13:2053. [PMID: 34696483 DOI: 10.3390/v13102053] [Reference Citation Analysis]
63 Takayama H, Sato T, Ikeda F, Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res. 2016;46:489-491. [PMID: 26297529 DOI: 10.1111/hepr.12578] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 9.9] [Reference Citation Analysis]
64 Block TM, Locarnini S, McMahon BJ, Rehermann B, Peters MG. Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics. Clin Infect Dis 2017;64:1283-8. [PMID: 28200098 DOI: 10.1093/cid/cix129] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
65 Chen S, Jia J, Gao Y, Li H, Fang M, Feng H, Guan W, Ji J, Gao Z, Gao C. Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients. Clin Chim Acta 2018;486:237-44. [PMID: 30025756 DOI: 10.1016/j.cca.2018.07.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
66 Zhang ZQ, Wang YB, Lu W, Liu DP, Shi BS, Zhang XN, Huang D, Li XF, Zhou XL, Ding RR. Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis. Ann Lab Med 2019;39:67-75. [PMID: 30215232 DOI: 10.3343/alm.2019.39.1.67] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
67 Inoue T, Tanaka Y. The Role of Hepatitis B Core-Related Antigen. Genes (Basel) 2019;10:E357. [PMID: 31075974 DOI: 10.3390/genes10050357] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
68 Li J, Wu Z, Wang GQ, Zhao H. Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients. Chin Med J (Engl) 2021;134:1160-7. [PMID: 33734135 DOI: 10.1097/CM9.0000000000001418] [Reference Citation Analysis]
69 Bartenschlager R, Cornberg M, Pietschmann T. [Personalized treatment of viral hepatitis of the present and the future : Hepatitis B, C, delta, and E]. Internist (Berl) 2017;58:666-74. [PMID: 28631044 DOI: 10.1007/s00108-017-0262-8] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Hu J, Liu K. Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application. Viruses. 2017;9. [PMID: 28335554 DOI: 10.3390/v9030056] [Cited by in Crossref: 120] [Cited by in F6Publishing: 110] [Article Influence: 24.0] [Reference Citation Analysis]
71 Osiowy C, Coffin C, Andonov A. Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy. Curr Treat Options Infect Dis 2016;8:177-93. [PMID: 27547127 DOI: 10.1007/s40506-016-0080-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
72 Lee JH, Kim HS. Current laboratory tests for diagnosis of hepatitis B virus infection. Int J Clin Pract 2021;:e14812. [PMID: 34487586 DOI: 10.1111/ijcp.14812] [Reference Citation Analysis]
73 Iossa D, Vitrone M, Liotti A, Portella G, Durante-Mangoni E, Zampino R. Hepatitis B core-related antigen to detect hepatitis B virus (HBV) reactivation in heart transplant recipients with past HBV infection: A pilot study. Clin Transplant 2019;33:e13574. [PMID: 31013373 DOI: 10.1111/ctr.13574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]